Vedanta Biosciences enrols first patient in VE416 phase 1b/2 food allergy clinical study

This article was originally published here

VE416 is Vedanta Biosciences’ live biotherapeutic product candidate being developed for treatment of food allergies, including persistent peanut allergy. The study, which is being conducted at MassGeneral Hospital

The post Vedanta Biosciences enrols first patient in VE416 phase 1b/2 food allergy clinical study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply